<DOC>
	<DOCNO>NCT02319837</DOCNO>
	<brief_summary>The purpose study assess enzalutamide plus leuprolide patient high-risk nonmetastatic prostate cancer progress radical prostatectomy radiotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study Enzalutamide Plus Leuprolide Patients With Nonmetastatic Prostate Cancer ( EMBARK )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate initial biopsy , without neuroendocrine differentiation , signet cell , small cell feature ; Prostate cancer initially treat radical prostatectomy radiotherapy ( include brachytherapy ) , curative intent ; PSA double time ≤ 9 month ; Screening PSA central laboratory ≥ 1 ng/mL patient radical prostatectomy ( without radiotherapy ) primary treatment prostate cancer least 2 ng/mL nadir patient radiotherapy primary treatment prostate cancer ; Serum testosterone ≥ 150 ng/dL ( 5.2 nmol/L ) . Prior present evidence distant metastatic disease assess radiographic imaging ; Prior hormonal therapy . Neoadjuvant/adjuvant therapy treat prostate cancer ≤ 36 month duration ≥ 9 month randomization , single dose short course ( ≤ 6 month ) hormonal therapy give rise PSA ≥ 9 month randomization allow . ; Prior cytotoxic chemotherapy , aminoglutethimide , ketoconazole , abiraterone acetate , enzalutamide prostate cancer ; Prior systemic biologic therapy , include immunotherapy , prostate cancer ; Major surgery within 4 week randomization ; Treatment 5α reductase inhibitor ( finasteride , dutasteride ) within 4 week randomization ; Known suspect brain metastasis active leptomeningeal disease ; History another invasive cancer within 3 year screen , exception fully treat cancer remote probability recurrence</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>